Incyte (Nasdaq:INCY) today announced financial results for the fourth quarter and full year ended December 31, 2025 and provided full year 2026 financial guidance.
BridgeBio is hoping infigratinib will get another shot at approval after the medicine hit the key goals of a phase 3 study in a form of dwarfism in children. The FDA granted infigratinib, which was ...
Phase 3 findings show infigratinib significantly improved annualized height velocity vs placebo in children living with achondroplasia. Topline data were announced from a phase 3 trial evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results